Zabdeno Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recurrent ebola outbreaks in high-risk regions, global emergency vaccination initiatives, increased funding for infectious disease prevention, early adoption of combination vaccine platforms, expansion of humanitarian immunization programs.

The growth in the forecast period can be attributed to increasing investments in outbreak preparedness, rising focus on next-generation viral vaccines, expansion of global immunization coverage, growing use of genomic surveillance for virus variants, increasing international health security collaborations. Major trends in the forecast period include expansion of ebola pre-exposure vaccination programs, increasing focus on two-dose vaccine compliance, growing stockpiling for outbreak preparedness, rising emphasis on cold-chain optimized vaccines, strengthening public-private vaccine partnerships.

The increasing incidence of Ebola viral disease is expected to drive the growth of the Zabdeno market. Ebola viral disease (EVD), caused by the Ebola virus of the Filoviridae family, is a severe and often fatal illness. The rise in Ebola cases is linked to factors such as increased human-wildlife interactions and insufficient surveillance and containment in high-risk regions, which facilitate virus transmission. Zabdeno, a vaccine developed to prevent Ebola, works by stimulating the immune system to recognize and combat the virus, reducing infection risk and preventing severe disease outcomes. For example, in January 2023, the World Health Organization reported approximately 164 Ebola cases (142 confirmed, 22 probable), with 77 deaths (55 among confirmed cases and 22 among probable cases) and 87 recoveries. Therefore, the increasing incidence of Ebola is driving the Zabdeno market.

Rising healthcare expenditure is expected to support the growth of the Zabdeno market. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, diagnosing, and treating health conditions. Spending is increasing due to advancements in medical technology, new diagnostic tools, innovative therapies, and higher costs for preventive measures. Increased healthcare expenditure enables greater investment in vaccines like Zabdeno and facilitates broader access to preventive treatments for infectious diseases. For instance, in December 2024, the Centers for Medicare & Medicaid Services reported that U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, approximately $14,570 per person. Therefore, rising healthcare expenditure is propelling the Zabdeno market.

Expanding immunization programs are expected to further drive the growth of the Zabdeno market. Immunization programs are public health initiatives designed to prevent infectious diseases through widespread vaccination. The growth of these programs is driven by increasing recognition of their effectiveness, as well as efforts to expand global vaccination coverage. These programs enhance Zabdeno’s impact by reducing disease burden, increasing herd immunity, and promoting healthier populations. For example, in April 2024, the Centers for Disease Control and Prevention reported that the International Coordinating Group (ICG) Ebola vaccine stockpile increased from 500,000 doses in 2022 to 518,890 doses by December 2023, a 3.8% rise within a year. Therefore, expanding immunization programs are driving the Zabdeno market.

Major companies operating in the zabdeno market are Johnson & Johnson Inc.

North America was the largest region in the zabdeno market in 2025. The regions covered in the zabdeno market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zabdeno market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the zabdeno market by increasing costs associated with imported vaccine raw materials, bioprocessing equipment, cold-chain logistics components, and specialized packaging required for two-dose regimens. Regions in Africa reliant on imported vaccines and distribution infrastructure are most affected, alongside manufacturing hubs in Europe facing higher input costs. These tariffs can delay procurement timelines and increase per-dose costs for public health agencies. However, they are also encouraging regional fill-finish capabilities, local vaccine manufacturing investments, and stronger supply chain resilience for outbreak response programs.

The zabdeno market research report is one of a series of new reports that provides zabdeno market statistics, including zabdeno industry global market size, regional shares, competitors with a zabdeno market share, detailed zabdeno market segments, market trends and opportunities, and any further data you may need to thrive in the zabdeno industry. This zabdeno market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zabdeno is a combination vaccine developed to provide protection against Ebola virus disease. It contains components targeting both Zaire ebolavirus and Sudan ebolavirus and is administered as a two-dose regimen for pre-exposure prophylaxis in individuals at high risk of Ebola virus exposure, helping prevent outbreaks.

The main types of Zabdeno include single-dose vaccines and two-dose vaccines. Single-dose vaccines provide rapid protection against Ebola virus disease with just one administration, useful for outbreak control in high-risk regions. Zabdeno is indicated for Ebola virus disease prevention and is distributed through hospitals, clinics, retail pharmacies, online pharmacies, and wholesale distributors. The end users include adults and geriatric populations.

The zabdeno market consists of sales of zabdeno (Ad26.ZEBOV) and mvabea (MVA-BN-Filo). Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.